已收盘 02-27 16:00:00 美东时间
0.000
NaN.00%
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer to lead the commercialization of AMT-130, a gene therapy for Huntington’s disease. With extensive experience in rare diseases and gene therapy, O’Keefe will oversee global commercial strategy and execution for AMT-130, aiming for U.S. launch in 2026. Her leadership is expected to advance uniQure’s mission of addressing severe unmet medical needs.
06-11 12:00